SCHEMBL20528837

SCHEMBL20528837

O=C(O)CCC(=O)N(CCNC(=O)CI)CCNC(=O)CI

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 1/20 0.36
PHF8 Q9UPP1 5/20 0.34
KDM2A Q9Y2K7 5/20 0.34
KDM4E B2RXH2 3/20 0.33
KDM5C P41229 3/20 0.33
EGLN1 Q9GZT9 3/20 0.33
KDM6B O15054 1/20 0.33
FOLH1 Q04609 1/20 0.33
KDM7A Q6ZMT4 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 2/20 0.32
ALKBH5 Q6P6C2 1/20 0.32
SUCNR1 Q9BXA5 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20528884 0.90 MAPK1 (0.40) PHF8KDM2AKDM7ALMNAHDAC3
SCHEMBL22344992 0.83 HDAC3 (0.31) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL23475951 0.82 ECE1 (0.36) ECE1PHF8KDM2AKDM4EKDM5C
SCHEMBL28331243 0.80 LMNA (0.34) ECE1PHF8KDM2AKDM7ALMNA
SCHEMBL22344990 0.79 HDAC3 (0.31) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28329845 0.79 HDAC3 (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20528863 0.78 ATM (0.41) ECE1KDM4ELMNAMAPK1TSHR
SCHEMBL10136034 0.77 DNM1 (0.47) PHF8DNM1KDM4AKDM4C
SCHEMBL964583 0.76 ECE1 (0.58) ECE1PHF8KDM2AKDM4EKDM5C
SCHEMBL2530630 0.76 MAPK1 (0.38) PHF8KDM2AKDM4EKDM7ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11471537-B2 Oligomer extended insulin-Fc conjugates NOVO NORDISK A/S (DK) 2022-10-18 US disclosed
US-20200261595-A1 Oligomer Extended Insulin-FC Conjugates NOVO NORDISK A/S (DK) 2020-08-20 US disclosed
EP-3606560-A2 OLIGOMER EXTENDED INSULIN-FC CONJUGATES Novo Nordisk A/S (DK) 2020-02-12 EP disclosed
WO-2018185131-A2 OLIGOMER EXTENDED INSULIN-FC CONJUGATES NOVO NORDISK A/S (DK) 2018-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261595-A1 Oligomer Extended Insulin-FC Conjugates IAPP, IDE, INSR ECE1 460/4885PHF8 3605/4885KDM2A 4785/4885
US-11471537-B2 Oligomer extended insulin-Fc conjugates IAPP, IDE, INSR ECE1 460/4885PHF8 3605/4885KDM2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.